论文部分内容阅读
目的：探讨阿奇霉素对慢性前列腺炎的疗效和安全性。方法：慢性前列腺炎病人８７例，年龄３２ａ±ｓ９ａ（２１～４７ａ），随机分成２组，分别服用阿奇霉素（４４例）０．５ｇ，ｐｏ，ｑｄ及复方磺胺甲唑（ＳＭＺＣｏ）２片（４３例），ｐｏ，ｂｉｄ，疗程６ｄ。服药前及服药后１，２ｗｋ分别行前列腺液（ＥＰＳ）常规及病原学检查，并监测血、尿常规及肝、肾功能。结果：阿奇霉素组病人痊愈率４８％和有效率８０％均高于ＳＭＺＣｏ组４２％和６５％（Ｐ＜０．０５）。２药对各类致病菌的清除率分别为７９％及６５％（Ｐ＜０．０５）；不良反应发生率分别为７％和１４％（Ｐ＜０．０５）。结论：阿奇霉素比ＳＭＺＣｏ对慢性前列腺炎具有较佳疗效，且服用方便，不良反应少。
Objective: To investigate the efficacy and safety of azithromycin in chronic prostatitis. Methods: A total of 87 patients with chronic prostatitis, aged 32a ± s9a (21 ~ 47a), were randomly divided into two groups. The patients were treated with azithromycin (44 cases) 0.5g, po, qd and SMZCo 2 tablets 43 cases), po, bid, course of treatment 6d. Prostate fluid (EPS) routine and etiological examination were performed before medication and 1, 2 weeks after taking the medication, and blood, urine and liver and kidney function were monitored. Results: The cure rate and the effective rate of 48% and 80% of patients in azithromycin group were significantly higher than those in SMZCo group (42% and 65% respectively) (P <0.05). The clearance rates of two drugs against various pathogenic bacteria were 79% and 65%, respectively (P <0.05). The incidence of adverse reactions were 7% and 14% respectively (P <0.05). Conclusion: Azithromycin has better curative effect on chronic prostatitis than SMZCo, and it is easy to take and less adverse reactions.